At a glance
ClinicalIndex Comparison RecordN/ACompleted· 33 enrolled
Drug / intervention
Infliximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Remicade Treatment Registry in Rheumatoid Arthritis I
In Brief
An observational study evaluating Infliximab for Rheumatoid Arthritis. Completed, enrolled 33 participants.
Detailed Summary
This study will gather information on the safety and efficacy of patients with rheumatoid arthritis (RA) who are starting treatment with infliximab for the first time. Patients will be treated in the usual manner according to local guidelines and normal clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedJul 2008
Primary CompletionOct 2008
TodayJul 2026
First PostedJul 29, 2008
Enrollment StartJan 1, 2006
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.9 years ago
Interventions
Infliximabdrug
Infliximab given in accordance with the local summary of product characteristics